Advanced Filters
noise
Found 840 clinical trials
K Kritleen Bawa

Cannabidiol Medication Intervention Trial

CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.

55 years of age All Phase 2
M Marc W Haut, PhD

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

45 - 85 years of age All Phase N/A
A April Riddle, BSRT

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data …

50 years of age All Phase 1
T Timber Bourassa, BS

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

A medicine that is FDA-approved for bone marrow stimulation (called sargramostim) will be tested for its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease over a six month treatment period.

60 - 85 years of age All Phase 2
M Margarita Mederos

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

50 - 85 years of age All Phase N/A

Perturbation Training Reduces Falls in People With AD

This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.

65 - 90 years of age All Phase N/A

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

High fat feeding (HFF) increases the risk of Alzheimer's disease (AD) but individuals who carry the AD risk gene E4 paradoxically improve after acute HFF. The investigators propose to further study this phenomenon with a clinical study to assess cerebral blood flow which can be measured by a technique called …

55 years of age All Phase N/A
R Rajagopal V Sekhar, MD

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine …

55 - 85 years of age All Phase N/A
K Karim BENNYS, MD, PhD

Blood Microbiota Signature of Alzheimer's Disease

This study aims to validate a difference in blood microbial signature between Alzheimer's patients and control subjects in order to propose potential innovative strategies

50 - 85 years of age All Phase N/A
A Azizi A Seixas, PhD

Combating Alzheimer's Through Sleep and Exercise

The purpose of this research is to see how sleep and exercise affects dementia risk over time.

45 - 80 years of age All Phase N/A

Simplify language using AI